Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Diagnosis and Management of Triple-Negative Breast Cancer (TNBC)
share announcement

Diagnosis and Management of Triple-Negative Breast Cancer (TNBC)

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: closed (15 December 2022) | Viewed by 5807

Special Issue Editor

Dr. Surabhi Chandra

E-Mail Website
Guest Editor
Department of Biology, University of Nebraska at Kearney, NE, USA
Interests: triple-negative breast cancer; microRNA; diabetes; receptor pharmacology; anticancer compound testing; G protein coupled receptor

Special Issue Information

Dear Colleagues,

Triple-negative breast cancer (TNBC) accounts for 10–15% of all breast cancers. Despite the relatively low occurrence, TNBC has a high mortality risk due to its highly heterogeneous, metastatic, and refractive characteristics, which pose challenges for effective treatment. There are no approved chemotherapeutics specifically for TNBC. The adjuvants and neoadjuvant prescribed for TNBC are not promising therapeutics; thus, there is a critical need for targeted therapy. In addition, underlying metabolic conditions such as diabetes further exacerbate TNBC, and patients with concurrent diabetes and TNBC have a poor prognosis.

This Special Edition is aimed at addressing the research advances in the area of TNBC, and the challenges in its treatment. In addition, metabolomics of TNBC in conjunction with underlying conditions such as diabetes will shed light on novel therapeutic targets.

The Special Issue calls for articles in the following areas:

  1. Transcriptomics and metabolomics of TNBC;
  2. Novel drug molecules, natural compounds, RNA therapeutics, gene therapy, etc. to treat TNBC;
  3. TNBC with diabetes: current trends and therapeutic approach;
  4. Innovative drug delivery methods to treat TNBC.

All submissions addressing all the above highlighted aspects on TNBC are welcome to this Special Issue. Thus, original articles, comprehensive reviews, and expert opinions are of the utmost interest, given the expansive scope of this area.

Dr. Surabhi Chandra
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • triple-negative breast cancer
  • novel therapy
  • metabolism
  • micro RNA
  • diabetes

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

15 pages, 1461 KiB  
Article
PD-L1-Positive High-Grade Triple-Negative Breast Cancer Patients Respond Better to Standard Neoadjuvant Treatment—A Retrospective Study of PD-L1 Expression in Relation to Different Clinicopathological Parameters
by Olga Stanowska, Olga Kuczkiewicz-Siemion, Małgorzata Dębowska, Wojciech P. Olszewski, Agnieszka Jagiełło-Gruszfeld, Andrzej Tysarowski and Monika Prochorec-Sobieszek
J. Clin. Med. 2022, 11(19), 5524; https://doi.org/10.3390/jcm11195524 - 21 Sep 2022
Cited by 4 | Viewed by 3216
Abstract
Triple negative breast cancer (TNBC) is typically a high-grade breast cancer with poorest clinical outcome despite available treatment modalities with chemo-, immuno- and radiotherapy. The status of tumor-infiltrating lymphocytes (TILs) is a prognostic factor closely related to programmed death ligand 1 (PD-L1) expressed [...] Read more.
Triple negative breast cancer (TNBC) is typically a high-grade breast cancer with poorest clinical outcome despite available treatment modalities with chemo-, immuno- and radiotherapy. The status of tumor-infiltrating lymphocytes (TILs) is a prognostic factor closely related to programmed death ligand 1 (PD-L1) expressed on T lymphocytes modulating antitumor immunity. Immune-checkpoint inhibitors (ICI) are showing promising results in a subset of breast cancer patients in both neo- and adjuvant settings. Pathologic complete response (pCR) after neoadjuvant treatment was found to be associated with better prognosis. We analyzed the prognostic and predictive significance of PD-L1 (SP142 assay) immunohistochemical expression on TNBC patients’ samples as illustrated by pCR with regard to its relation to treatment regimen, stage, BRCA mutational status and outcome. Furthermore, we analyzed a few other clinicopathological parameters such as age, TILs and proliferation index. The study highlighted a positive role of PD-L1 evaluation for personalized pCR probability assessment. Although considerable research was made on comparison of PD-L1 level in TNBC with different patient parameters, to our best knowledge, the relation of PD-L1 status to pCR while taking treatment regimen and stage into consideration was so far not investigated. Full article
(This article belongs to the Special Issue Diagnosis and Management of Triple-Negative Breast Cancer (TNBC))
►▼ Show Figures

Figure 1

Other

Jump to: Research

15 pages, 1787 KiB  
Systematic Review
Efficacy of PARP Inhibitor, Platinum, and Immunotherapy in BRCA-Mutated HER2-Negative Breast Cancer Patients: A Systematic Review and Network Meta-Analysis
by Wanyi Sun, Yun Wu, Fei Ma, Jinhu Fan and Youlin Qiao
J. Clin. Med. 2023, 12(4), 1588; https://doi.org/10.3390/jcm12041588 - 17 Feb 2023
Cited by 2 | Viewed by 2158
Abstract
The optimal treatment regimen for breast cancer patients with gBRCA mutations remains controversial given the availability of numerous options, such as platinum-based agents, polymerase inhibitors (PARPis), and other agents. We included phase II or III RCTs and estimated the HR with 95% CI [...] Read more.
The optimal treatment regimen for breast cancer patients with gBRCA mutations remains controversial given the availability of numerous options, such as platinum-based agents, polymerase inhibitors (PARPis), and other agents. We included phase II or III RCTs and estimated the HR with 95% CI for OS, PFS, and DFS, in addition to the OR with 95% CI for ORR and pCR. We determined the treatment arm rankings by P-scores. Furthermore, we carried out a subgroup analysis in TNBC and HR-positive patients. We conducted this network meta-analysis using R 4.2.0 and a random-effects model. A total of 22 RCTs were eligible, involving 4253 patients. In the pairwise comparisons, PARPi + Platinum + Chemo was better than PARPi + Chemo for OS (in whole study group and in both subgroups) as well as PFS. The ranking tests demonstrated that PARPi + Platinum + Chemo ranked first in PFS, DFS, and ORR. Platinum + Chemo showed higher OS than PARPi + Chemo. The ranking tests for PFS, DFS, and pCR indicated that, except for the best treatment (PARPi + Platinum + Chemo) containing PARPi, the second and third treatments were platinum monotherapy or platinum-based chemotherapy. In conclusion, PARPi + Platinum + Chemo might be the best regime for gBRCA-mutated BC. Platinum drugs showed more favorable efficacy than PARPi in both combination and monotherapy. Full article
(This article belongs to the Special Issue Diagnosis and Management of Triple-Negative Breast Cancer (TNBC))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop